APO RESEARCH · REPORT
Gastroparesis Drugs
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
Product & engineering
Understand the product.
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
Selected research
Industry Research
Gastroparesis Drugs Industry Research Report 2026
Market perspective
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
North America is the largest consumer of Gastroparesis Drugs in global market.The second place is Europe, following North America.
Market is not concentrated. Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva and Johnson & Johnsonare the leaders of the industry, and hold the key technologies and patent, with high-end customers.
Read the full market overview
Report Scope
This report quantifies the global Gastroparesis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastroparesis Drugs Market by Company
Sumitomo
Cadila Pharmaceuticals
Sanofi
Teva
Johnson & Johnson
Pfizer
Kyowa Kirin Pharmaceuticals
Hanmi Pharm
Ani Pharmaceuticals
Gastroparesis Drugs Segment by Type
Prokinetic Agents
Antiemetic Agents
Others
Gastroparesis Drugs Segment by Application
Diabetic Gastroparesis
Idiopathic Gastroparesis
Gastroparesis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastroparesis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastroparesis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastroparesis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gastroparesis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gastroparesis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gastroparesis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prokinetic Agents
- Antiemetic Agents
- Others
Applications
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
Companies covered
- Sumitomo
- Cadila Pharmaceuticals
- Sanofi
- Teva
- Johnson & Johnson
- Pfizer
- Kyowa Kirin Pharmaceuticals
- Hanmi Pharm
- Ani Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gastroparesis Drugs Market Size (2021-2032)
- 2.2.2 Global Gastroparesis Drugs Sales (2021-2032)
- 2.2.3 Global Gastroparesis Drugs Market Average Price (2021-2032)
- 2.3 Gastroparesis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Prokinetic Agents
- 2.3.3 Antiemetic Agents
- 2.3.4 Others
- 2.4 Gastroparesis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Diabetic Gastroparesis
- 2.4.3 Idiopathic Gastroparesis
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gastroparesis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gastroparesis Drugs Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Gastroparesis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Gastroparesis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Gastroparesis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gastroparesis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gastroparesis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Gastroparesis Drugs, Established Date
- 3.9 Global Gastroparesis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sumitomo
- 4.1.1 Sumitomo Company Information
- 4.1.2 Sumitomo Business Overview
- 4.1.3 Sumitomo Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sumitomo Gastroparesis Drugs Product Portfolio
- 4.1.5 Sumitomo Recent Developments
- 4.2 Cadila Pharmaceuticals
- 4.2.1 Cadila Pharmaceuticals Company Information
- 4.2.2 Cadila Pharmaceuticals Business Overview
- 4.2.3 Cadila Pharmaceuticals Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cadila Pharmaceuticals Gastroparesis Drugs Product Portfolio
- 4.2.5 Cadila Pharmaceuticals Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Gastroparesis Drugs Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Teva
- 4.4.1 Teva Company Information
- 4.4.2 Teva Business Overview
- 4.4.3 Teva Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Teva Gastroparesis Drugs Product Portfolio
- 4.4.5 Teva Recent Developments
- 4.5 Johnson & Johnson
- 4.5.1 Johnson & Johnson Company Information
- 4.5.2 Johnson & Johnson Business Overview
- 4.5.3 Johnson & Johnson Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Johnson & Johnson Gastroparesis Drugs Product Portfolio
- 4.5.5 Johnson & Johnson Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Gastroparesis Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Kyowa Kirin Pharmaceuticals
- 4.7.1 Kyowa Kirin Pharmaceuticals Company Information
- 4.7.2 Kyowa Kirin Pharmaceuticals Business Overview
- 4.7.3 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Product Portfolio
- 4.7.5 Kyowa Kirin Pharmaceuticals Recent Developments
- 4.8 Hanmi Pharm
- 4.8.1 Hanmi Pharm Company Information
- 4.8.2 Hanmi Pharm Business Overview
- 4.8.3 Hanmi Pharm Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hanmi Pharm Gastroparesis Drugs Product Portfolio
- 4.8.5 Hanmi Pharm Recent Developments
- 4.9 Ani Pharmaceuticals
- 4.9.1 Ani Pharmaceuticals Company Information
- 4.9.2 Ani Pharmaceuticals Business Overview
- 4.9.3 Ani Pharmaceuticals Gastroparesis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ani Pharmaceuticals Gastroparesis Drugs Product Portfolio
- 4.9.5 Ani Pharmaceuticals Recent Developments
5 Global Gastroparesis Drugs Market Scenario by Region
- 5.1 Global Gastroparesis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gastroparesis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Gastroparesis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Gastroparesis Drugs Sales by Region: 2027-2032
- 5.3 Global Gastroparesis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Gastroparesis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Gastroparesis Drugs Revenue by Region: 2027-2032
- 5.4 North America Gastroparesis Drugs Market Facts & Figures by Country
- 5.4.1 North America Gastroparesis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gastroparesis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Gastroparesis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gastroparesis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Gastroparesis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gastroparesis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Gastroparesis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gastroparesis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gastroparesis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gastroparesis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gastroparesis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gastroparesis Drugs Market Facts & Figures by Country
- 5.7.1 South America Gastroparesis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gastroparesis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Gastroparesis Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Gastroparesis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gastroparesis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gastroparesis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gastroparesis Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gastroparesis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Gastroparesis Drugs Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Gastroparesis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Gastroparesis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Gastroparesis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gastroparesis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Gastroparesis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gastroparesis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Gastroparesis Drugs Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Gastroparesis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Gastroparesis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Gastroparesis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gastroparesis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Gastroparesis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gastroparesis Drugs Value Chain Analysis
- 8.1.1 Gastroparesis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gastroparesis Drugs Production Mode & Process
- 8.2 Gastroparesis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gastroparesis Drugs Distributors
- 8.2.3 Gastroparesis Drugs Customers
9 Global Gastroparesis Drugs Analyzing Market Dynamics
- 9.1 Gastroparesis Drugs Industry Trends
- 9.2 Gastroparesis Drugs Industry Drivers
- 9.3 Gastroparesis Drugs Industry Opportunities and Challenges
- 9.4 Gastroparesis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst